Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Otsuka

Status and phase: Terminated; Phase 3

Conditions: Agitation in Patients With Dementia of the Alzheimer's Type

Treatments: Drug: Placebo; Drug: AVP-786

Study type: Interventional

Funder types: Industry

Identifiers

NCT04464564

2020-000799-39 (EudraCT Number)

2023-504991-31-00 (EU Trial (CTIS) Number)

20-AVP-786-307

Details and patient eligibility

About

This study was conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.

Full description

Eligible participants for this study had a diagnosis of probable Alzheimer's disease (AD) and had clinically significant, moderate/severe agitation secondary to AD.

This was multicenter, randomized, double-blind, placebo-controlled study, consisting of 12 weeks of treatment. Screening occurred within 4 weeks prior to randomization. Following screening procedures for assessment of inclusion and exclusion criteria, eligible participants were randomized into the study.

236 participants were randomized into the study.

Study medication was administered orally twice daily from Day 1 through Day 85.

Enrollment: 241 patients

Sex: All

Ages: 50 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants with a diagnosis of probable Alzheimer's disease according to the 2011 Neuropsychiatric Inventory Agitation/Aggression (NPI-AA) working groups criteria
• Participants with clinically significant, moderate-to-severe agitation for at least 2 weeks prior to Screening that interferes with daily routine per the Investigator's judgment
• Participants who require pharmacotherapy for the treatment of agitation per the Investigator's judgment after an evaluation of reversible factors and a course of nonpharmacological interventions
• Diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation.
• Participants meeting an additional predetermined blinded eligibility criterion, which will remain blinded to the clinical study site Investigators and staff
• Participants with a reliable caregiver who is able and willing to comply with all study procedures, including adherence to administering study drug and not administering any prohibited medications during the course of the study, and who spends a minimum of 2 hours per day for 4 days per week with the participant

Exclusion criteria

• Participants with dementia predominantly of the non-Alzheimer's type (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia)
• Participants with symptoms of agitation that are not secondary to Alzheimer's dementia (e.g., secondary to pain, other psychiatric disorder, or delirium)
• Participants with co-existent clinically significant or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g., malignancy [except skin basal-cell carcinoma], poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, or unstable valvular heart disease)
• Participants with myasthenia gravis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

241 participants in 3 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Participants received AVP-786 matching placebo capsules, twice a day, over a 12-week treatment period.

Treatment:

Drug: Placebo

AVP-786-18

Experimental group

Description:

Participants received AVP-786-18 (d6-DM 18 milligrams (mg)/Q 4.9 mg), twice a day, over a 12-week treatment period.

Treatment:

Drug: AVP-786

AVP-786-42.63

Experimental group

Description:

Participants received AVP-786-42.63 (d6-DM 42.63 mg/Q 4.9 mg) capsules, twice a day, over a 12-week treatment period.

Treatment:

Drug: AVP-786